NEW YORK (GenomeWeb News) — Protein therapy products maker GenOdyssee today said it will provide Baxter with its technology, intellectual property, and integrated processes.
 
Under the agreement, Baxter will use these platforms to discover "novel blood clotting factors" in the course of its hemophilia research, and will develop and market any "commercially viable products" resulting from the partnership.
 
Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.